12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISIS-APOARx: Phase I started

Isis began a blinded, placebo-controlled, dose-escalation Phase I trial to evaluate single and multiple doses of...

Read the full 57 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >